Aptabio, a developer of refractory anticancer drugs and diabetic complication treatments (CEO Sujin Lee), announced on the 2nd that it will participate in the '2023 BIO International Convention' (hereinafter BIO USA).
BIO USA is the world's largest bio convention event hosted by the Biotechnology Innovation Organization (BIO) in the United States. This year, it will be held for four days from the 5th to the 8th (local time) at the Boston Convention and Exhibition Center in the U.S.
The event will bring together more than 10,000 attendees from over 5,000 companies across 65 countries worldwide, including major global big pharma and well-known domestic and international pharmaceutical companies, to share research and development achievements and seek partnerships.
Aptabio plans to focus on discussions regarding technology exports for ▲‘Isuzinaxib,’ a diabetic nephropathy treatment preparing for clinical phase 2b ▲an acute kidney injury treatment currently in clinical phase 2 ▲a next-generation immune anticancer drug targeting cancer-associated fibroblasts (CAF) about to enter clinical trials ▲and a new pipeline next-generation macular degeneration treatment (AB-19). Since these pipelines are attracting significant interest from global big pharma, the company’s strategy is to highlight the advantages of the related platform technologies.
In particular, new drugs for patients with difficult-to-treat diseases such as diabetic nephropathy and acute kidney injury, which are diabetic complication treatments, are disease groups where development is very challenging without platform technology. The company has been recognized for its platform technology capabilities by continuously developing from the early stages through clinical phase 2b.
An Aptabio representative expressed expectations, saying, “Since key executives from global pharmaceutical companies will be present at this event, we believe we can sufficiently highlight Aptabio’s technological capabilities in the global market.”
Meanwhile, next-generation immune anticancer drugs targeting cancer-associated fibroblasts (CAF) and next-generation macular degeneration treatments (AB-19) are currently among the most interesting fields for global pharmaceutical companies. Based on research results that integrate Aptabio’s core technologies, the company is securing worldwide patents and entering clinical development stages, thus receiving focused attention from global pharmaceutical companies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
